Literature DB >> 20667071

A comparison of methods of pathogen inactivation of FFP.

G Rock1.   

Abstract

INTRODUCTION: Current methods for pathogen inactivation of plasma involve four major processes using solvent-detergent (SD), methylene blue (MB), amotosalen and riboflavin as additives. Three of these methods involve the use of visible or ultraviolet light.
METHODS: A comparison of the four methods was made using publications in Medline, Pubmed, Embase and Biosis to obtain data on the logistics of use, the quality of the plasma proteins and the effectiveness of pathogen inactivation.
RESULTS: Three of the methods, MB, amotosalen and riboflavin, are designed for use in a blood bank; the SD method is generally applied at a centralized manufacturing centre and involves large plasma pools. All methods result in a reduction in protein values with the per cent retention of FVIII activity in the range of 67-78% and fibrinogen of 65-84%. Protein S and alpha(2)-antiplasmin are lower following solvent-detergent treatment. Alterations in fibrinogen structure have been reported with methylene blue. DISCUSSION: Three of the methods are designed for small volume use in a blood bank. All four methods have some effect on the coagulant proteins; however, the final concentrations are within regulated limits. While there is variability in the effectiveness against pathogens, direct comparison is difficult because of the methodologies used. Nonetheless, all are effective in inactivating HIV and other lipid-enveloped pathogens. Clinical studies on the effectiveness of these products are surprisingly sparse, and no randomized clinical trials have yet been performed with amotosalen or riboflavin plasmas.
© 2010 The Author(s). Vox Sanguinis © 2010 International Society of Blood Transfusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20667071     DOI: 10.1111/j.1423-0410.2010.01374.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  27 in total

1.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

2.  Freeze-dried plasma enhances clot formation and inhibits fibrinolysis in the presence of tissue plasminogen activator similar to pooled liquid plasma.

Authors:  Benjamin R Huebner; Ernest E Moore; Hunter B Moore; Angela Sauaia; Gregory Stettler; Monika Dzieciatkowska; Kirk Hansen; Anirban Banerjee; Christopher C Silliman
Journal:  Transfusion       Date:  2017-05-12       Impact factor: 3.157

Review 3.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

4.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

5.  Usutu virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-12-23       Impact factor: 3.747

6.  Factor VIII and fibrinogen recovery in plasma after Theraflex methylene blue-treatment: effect of plasma source and treatment time.

Authors:  André Rapaille; Stefan Reichenberg; Tome Najdovski; Nicolas Cellier; Nicolas de Valensart; Véronique Deneys
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 7.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

8.  Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.

Authors:  Joseph B Babigumira; Solomon J Lubinga; Emma Castro; Brian Custer
Journal:  Blood Transfus       Date:  2016-11-16       Impact factor: 3.443

9.  Zika Virus (ZIKV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-10-14       Impact factor: 3.747

10.  Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction.

Authors:  Jerard Seghatchian; Wilhelm G Struff; Stefan Reichenberg
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.